SANTA CLARA, California, December 19 /PRNewswire/ --

- Marvell PXA 300 Application Processor Delivers Both Outstanding Multimedia and Optimal Business Applications Functionality

Marvell, (Nasdaq: MRVL), a leader in storage, communications, and consumer silicon solutions, and Samsung, announced the availability of the Samsung SPH-M4650 PDA phone with the Marvell(R) PXA 300 application processor running on Korea's LG Telecom network. The Marvell PXA 300 application processor enables high-end graphics, gaming, and multimedia capabilities for the Samsung SPH-M4650 as well as delivering optimal business applications while consuming ultra-low levels of power. The Samsung SPH-M4650 runs on the Microsoft Windows Mobile 6.0 Professional operating system.

AMSTERDAM, December 19 /PRNewswire/ --

- FDA Offers Special Protocol Assessment for Reviroc

Kiadis Pharma announced today that it has successfully completed an End of Phase II meeting for Reviroc with the U.S. Food and Drug Administration (FDA). Reviroc is under development for elimination of cancer cells from an autologous graft in bone marrow transplantations for end-stage blood cancer patients. The FDA agreed that the data from the completed phase II clinical Reviroc trial is sufficient to support the start of a phase III study. The FDA offered Kiadis Pharma its Special Protocol Assessment (SPA) procedure allowing Kiadis Pharma to work directly with the FDA to optimize the clinical design of the trial.

KING OF PRUSSIA, Pennsylvania, December 19 /PRNewswire/ --

- High levels of Type III von Willebrand Disease, a serious, hereditary bleeding disorder, found in region

NEW YORK, December 19 /PRNewswire/ --

- Digital Media Vet Kaleil Isaza Tuzman to become Chairman and CEO and to Appoint new Slate of Directors

ROO Group (OTC Bulletin Board: RGRP) announced today that the company has entered into an Executive Management Agreement with KIT Capital pursuant to which it has agreed to appoint Kaleil Isaza Tuzman as Chairman and Chief Executive Officer commencing on January 9th, 2008. Mr. Isaza Tuzman will succeed Robert Petty, who will retain the office of Vice-Chairman of the Board of Directors and Founder.

GENEVA, Switzerland, December 19 /PRNewswire/ -- Merck KGaA announced today that it has entered into a worldwide licensing and collaboration agreement on behalf of its Merck Serono division with Idera Pharmaceuticals, Inc. of Cambridge, Massachusetts, USA (Nasdaq: IDRA) for the research, development, and commercialisation of Idera's Toll-like Receptor 9 (TLR9) agonists for the treatment of cancer.